Trisalus Life Sciences, Inc. (TLSI) has disclosed a new risk, in the Debt & Financing category.
Trisalus Life Sciences, Inc. faces significant financial risk as it operates under a Credit Agreement with OrbiMed that allows borrowing up to $50 million, with strict covenants limiting company actions and requiring substantial asset collateral. The company must maintain high levels of unrestricted cash, and failure to meet revenue milestones could restrict further borrowing under the Loan Facility, potentially hampering operations. As the company’s performance and cash flow are impacted by various factors, some uncontrollable, there is a risk that Trisalus may not generate enough cash to service its debt, leading to possible asset sales, capital raising, or debt restructuring to avoid default.
The average TLSI stock price target is $16.00, implying 70.39% upside potential.
To learn more about Trisalus Life Sciences, Inc.’s risk factors, click here.
